1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND study
    Meeting Abstract

    Duell, J.; Abrisqueta, P.; Andre, M.; Augustin, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Kalakonda, N.; Liberati, A. M.; Maddocks, K. J.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Five‐year subgroup analysis of tafasitamab + lenalidomide from the phase II L‐MIND study in patients with relapsed or refractory diffuse large B‐cell lymphoma
    Meeting Abstract

    Duell, J.; Abrisqueta, P.; Dreyling, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Maddocks, K. J.; Menne, T.; Nagy, Z.; Tournilhac, O.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Tafasitamab plus lenalidomide versus standard of care as second‐line (2L) therapy for patients with R/R DLBCL: A post hoc internal 2L analysis of L‐MIND (IN 2L‐MIND)
    Meeting Abstract

    Sehn, L. H.; Kuruvilla, J.; Salles, G.; Maddocks, K. J.; Koch, C.; Xue, Z.; Amoloja, T.; Amin, A.; Duell, J.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Patient‐ versus clinician‐reported symptoms in the POLARIX study
    Meeting Abstract

    Thompson, C. A.; Mehta‐Shah, N.; Flowers, C.; Salles, G.; Tilly, H.; Chua, N.; Casasnovas, R.; Miall, F.; Kim, T. M.; Tsai, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Patterns of disease failure by response to induction therapy in a large cohort of patients with primary central nervous system lymphoma
    Meeting Abstract

    Tringale, K. R.; Yahalom, J.; Scordo, M.; White, C.; Zhang, Z.; Grommes, C.; Imber, B.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Evolving consolidation patterns and modern outcomes for a large longitudinal cohort of primary CNS lymphoma patients
    Meeting Abstract

    Imber, B. S.; Tringale, K.; White, C.; Zhang, Z.; Scordo, M.; Yahalom, J.; Grommes, C.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Radiotherapy as an effective bridge for chemo‐refractory or progressive secondary CNS lymphoma
    Meeting Abstract

    Cederquist, G.; Tringale, K.; Hajj, C.; Hubbeling, H.; Sarkar, R.; Ma, J.; Dreyfuss, A.; Fregonese, B.; Lee, J.; Salles, G.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Treatment outcomes of limited stage grade 3A follicular lymphoma
    Meeting Abstract

    Sarkar, R. R.; Lee, J.; Zhang, Z.; Zelenetz, A.; Salles, G.; Yahalom, J.; Imber, B.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • A single‐center experience of low‐dose radiotherapy for primary extranodal marginal zone lymphoma of bronchus‐associated lymphoid tissue (BALT)
    Meeting Abstract

    Freret, M. E.; Tringale, K. R.; Imber, B. S.; Joffe, E.; Yahalom, J.; Hajj, C.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for early‐stage classical Hodgkin Lymphoma: Updated results from an ongoing phase 2 study (SGN35‐027 Part C)
    Meeting Abstract

    Abramson, J. S.; Straus, D.; Bartlett, N.; Burke, J. M.; Lynch, R. C.; Domingo‐Domenech, E.; Hess, B.; Schuster, S.; Linhares, Y.; Ramchandren, R.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save